MKI67 and breast cancer: Further analysis demonstrated that among HR positive breast cancer patients, HER2-low patients typically presents a lower incidence of grade III tumors, a lower Ki-67 proliferation index, and fewer TP53 mutations compared with HER2-zero patients.